Skip to content
Menu

IDEXX Laboratories, Inc. IDXX

Full chart Compare
Set alert

Price alert · IDXX

All alert types
690.24 USD -10.41 (-1.49%)

Regular-session close

690.24 0.00 0.00%

After hours · Nov 17, 4:01 PM ET

687.72 Day range 706.76
504.70 52-week range 766.68
YTD
+2.03%
1 year
+3.17%
Market cap
54.38B
Revenue (ttm)
4.66B
Profit margin
25.36%
EPS (ttm)
14.97
Shares out
78.79M
P/E ratio
46.11
Forward P/E
40.86
YTD return
+2.03%
1-year return
+3.17%
50-day average
565.71
Volume
400.57K
Avg volume
564.68K
Open
700.66
Previous close
700.65
Day's range
687.72 – 706.76
52-week range
504.70 – 766.68
Beta
1.54
Analysts
Buy
Price target
717.17 (+3.9%)
Earnings date
Feb 1, 2027

5D +7.06 (+1.03%)

690700710WedThuFriMonTue690.24

Key statistics

200-day average
572.50
Enterprise value
55.98B
PEG ratio
3.25
Price / sales
11.66
Price / book
29.09
Revenue growth
9.90%
Free cash flow
1.06B
Total cash
197.54M
Total debt
972.96M
Return on equity
68.93%
Short % of float
3.42%

Fundamental scorecard

17 of 25 checks passed on IDXX’s reported financials

ValueGrowthProfitabilityHealthDividend

17of 25 checks passed

  • Value 3 of 5
  • Growth 5 of 5
  • Profitability 5 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IDXX Revenue — quarterly 1.21B
IDXX Net income — quarterly 317.14M
IDXX EPS — quarterly 4.02

Earnings

IDXX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 1, 2027Dec 30, 20263.30———
Nov 2, 2026Sep 30, 20263.733.96+0.23+6.17%
Aug 4, 2026Jun 30, 20263.944.27+0.33+8.38%
May 5, 2026Mar 31, 20263.413.47+0.06+1.76%
Feb 2, 2026Dec 31, 20252.933.08+0.15+5.12%
Nov 3, 2025Sep 30, 20253.143.40+0.26+8.28%

Upgrades / downgrades

IDXX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 3, 2026Morgan StanleymainOverweightOverweight
Nov 3, 2026UBSmainNeutralNeutral
Oct 27, 2026UBSmainNeutralNeutral
Oct 16, 2026JP MorganmainOverweightOverweight
Oct 12, 2026Keybancinit—Sector Weight
Aug 11, 2026BarclaysmainOverweightOverweight

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
idexx.com

News

Your note

Sign in to keep a note on IDXX — it syncs with the Stock Master app.

Insider holders

IDXX insider holders
InsiderRelationLatest transactionDateShares held
EMERSON ANDREWChief Financial OfficerConversion of Exercise of derivative securityAug 19, 20264,421
ERICKSON MICHAEL GOfficerConversion of Exercise of derivative securityFeb 18, 202615,092
FENNELL GEORGEOfficerConversion of Exercise of derivative securityMay 31, 202610,433
HUNT NIMRATA KOfficerSaleMar 2, 202618,300
KINGSLEY LAWRENCE DDirectorSaleSep 3, 20269,568
LANE MICHAEL JOfficerConversion of Exercise of derivative securityFeb 12, 20268,615

Institution ownership

IDXX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.28%8,100,2195.59BSep 29, 2026
Vanguard Capital Management LLC6.55%5,156,9143.56BSep 29, 2026
Vanguard Portfolio Management LLC5.02%3,955,9272.73BSep 29, 2026
State Street Corporation4.77%3,761,3622.60BSep 29, 2026
Invesco Ltd.4.28%3,373,6632.33BSep 29, 2026
Geode Capital Management, LLC3.33%2,620,7031.81BSep 29, 2026

Fund ownership

IDXX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%2,504,3271.73BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%2,043,0871.41BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.17%1,709,2091.18BJun 29, 2026
Invesco QQQ Trust, Series 12.09%1,645,0671.14BSep 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%1,050,026724.77MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%1,023,837706.69MSep 29, 2026